Dapagliflozin plus gliclazide combination improves blood sugar control in type 2 diabetes
Last updated June 11, 2026
Key finding
Combining dapagliflozin with gliclazide improves blood sugar control more than dapagliflozin alone in type 2 diabetes.
This 16-week study tested whether combining two diabetes medications works better than one alone. Researchers in India randomly assigned 244 adults with type 2 diabetes to receive either dapagliflozin plus gliclazide together, or dapagliflozin alone. All participants were already taking metformin but their blood sugar remained poorly controlled. The combination reduced HbA1c by 1.79% compared to 1.48% with dapagliflozin alone, a meaningful difference. Fasting and after-meal blood sugar also improved more with the combination. Only 5 patients taking the combination experienced low blood sugar events, and all recovered. The combination appears to help improve blood sugar control in people whose diabetes is not well-managed with metformin alone.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
Randomized Controlled Trials (RCTs)
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
Combining dapagliflozin with gliclazide improves blood sugar control more than dapagliflozin alone in type 2 diabetes.
Published in
Journal Reference
Publication details and source links for this paper.
Erande SG, Raykantiwar A, Shejole V, et al. A Randomized, Multicenter Study Evaluating the Efficacy, Safety and Tolerability of Dapagliflozin + Gliclazide Fixed Dose Combination Over Dapagliflozin Monotherapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Metformin Monotherapy. Cureus. 2026;18(2):e103676. doi:10.7759/cureus.103676
Main Effects
HbA1c → ↓ (moderate improvement, additional 0.3% reduction)
Fasting blood sugar → ↓ (moderate improvement)
After-meal blood sugar → ↓ (moderate improvement)
Evidence Suggest
- The combination of dapagliflozin plus gliclazide appears to lower HbA1c more than dapagliflozin alone in people taking metformin
- Fasting and after-meal blood sugar levels also improved more with the combination
- Low blood sugar events were uncommon and not serious
Who this applies to
Adults aged 18-65 with type 2 diabetes whose blood sugar remains poorly controlled (HbA1c 8-10%) despite taking metformin at adequate doses for at least 3 months. Does not apply to people with reduced kidney function, type 1 diabetes, or very high blood sugar levels.
Keep in Mind
Study participants were from India only, so results may not fully apply to other populations
Between the Lines
- Short 16-week study period
- Open-label design (not blinded)
- Excluded people with kidney problems
- Conducted only in India
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.